Enclomiphene Interactions: What Studies Cover on Alcohol, Caffeine and Food

What This Page Covers

Enclomiphene is the trans-isomer of clomiphene citrate, a triphenylethylene compound classified as a selective estrogen receptor modulator. Questions about how it behaves alongside everyday substances — alcohol, caffeine, food or fasting — and alongside other endocrine-active compounds are common. This page separates two very different categories: findings that appear in published studies, and mechanistic reasoning that researchers use in the absence of a study. Every published finding below carries its PubMed link in the same passage. Where no study exists, that is stated plainly rather than filled in with inference presented as evidence.

This page is for educational purposes only and is not medical advice; consult a licensed physician about any medical question, medication or combination of substances. Nothing here describes a protocol, a regimen, or a combination anyone should or should not use.

The Starting Point: What Has Actually Been Measured

The most directly relevant human pharmacology in the verified literature comes from a study that evaluated the relationship between plasma concentrations of en- and zuclomiphene and induction of ovulation in anovulatory women being treated with clomiphene citrate (PMID 18353317). That work is important context for any interaction question because it established that the two isomers can be measured separately in plasma and that researchers examined whether those circulating concentrations related to a clinical endpoint. It did not, however, examine alcohol, caffeine, meals, fasting state, or co-administered drugs as variables.

Two further studies describe activity of clomiphene and its isomers outside the estrogen receptor. One reported that clomiphene and its isomers blocked Ebola virus particle entry and infection with similar potency, an activity the authors framed as having potential therapeutic implications (PMID 27490565). Another reported that the anti-oestrogens clomiphene and nafoxidine inhibited volume-regulated anion channels in cultured endothelial cells (PMID 11156570). Both were laboratory models, not interaction studies, but they matter to this topic because they show the molecule engages targets beyond the receptor it is usually discussed in terms of.

Finally, an endocrine model study reported on regulation of plasma gonadotropin II secretion by sex steroids, aromatase inhibitors, and antiestrogens in the protandrous black porgy (PMID 11399474). That study is the closest thing in this citation set to a "combination" investigation, in that multiple classes of endocrine-active agents were examined against the same gonadotropin readout — in a fish species, not in humans.

Enclomiphene and Alcohol: What the Literature Shows

There is no published clinical or preclinical interaction study in the verified literature reviewed here that administered enclomiphene together with ethanol and measured a pharmacokinetic or endocrine outcome. That is the whole of the evidence position: an absence, not a negative finding. An absence of a study is not a statement that nothing happens, and it is equally not a statement that something does.

Mechanistic reasoning researchers use (labelled as reasoning, not evidence)

When no interaction trial exists, pharmacologists typically reason from three properties of the molecule and the co-substance: shared metabolic pathways, shared physiological axes, and shared target tissues. For enclomiphene, the reasoning usually runs as follows:

• Hepatic handling. Triphenylethylene compounds undergo hepatic metabolism, and ethanol is also cleared hepatically, so researchers raise the theoretical question of competing or altered hepatic processing. No study in this citation set tested that question for enclomiphene.
• The hypothalamic–pituitary–gonadal axis. Antiestrogens are studied specifically because they alter gonadotropin output, as reported in the black porgy model where antiestrogens were among the agents examined against plasma gonadotropin II secretion (PMID 11399474). Because ethanol is widely discussed as an axis-active substance, the mechanistic argument is that two axis-active inputs could produce a combined effect. That argument has not been tested with enclomiphene in the literature cited here.
• Measurable exposure. Because plasma concentrations of the individual isomers can be quantified, as the study in anovulatory women demonstrated (PMID 18353317), researchers note that an ethanol interaction study is methodologically feasible — the analytical tools exist. It simply has not been reported in this set.

Enclomiphene and Caffeine: What the Literature Shows

No study in the verified literature administered enclomiphene with caffeine or examined caffeine as a covariate. Again, that is an absence rather than a finding of no effect.

The mechanistic reasoning researchers apply here is narrower than for alcohol. Caffeine is a methylxanthine with adenosine-receptor and phosphodiesterase activity, and the pharmacological questions usually raised are whether cytochrome-mediated metabolism overlaps and whether downstream signalling converges. One reason this question is raised at all for clomiphene-class compounds is the demonstration of non-receptor activity: the study of cultured endothelial cells reported inhibition of volume-regulated anion channels by clomiphene (PMID 11156570), which illustrates that these molecules can act on ion-transport machinery in addition to nuclear receptors. Whether any such activity intersects with methylxanthine pharmacology at physiologically relevant exposures was not addressed in that study, and no follow-up in this citation set tested it.

Food, Fasting and Absorption: What the Literature Shows

No food-effect study — the standard fed-versus-fasted crossover design used to characterise oral absorption — appears in the verified literature for enclomiphene. Nothing in this citation set reports a change in absorption, peak concentration or time-to-peak attributable to a meal, meal composition, or fasting duration.

What the literature does establish is that circulating isomer concentrations are quantifiable and were correlated against a clinical endpoint in treated women (PMID 18353317). Researchers point to that kind of assay work as the prerequisite for any future food-effect investigation, because a meaningful fed-versus-fasted comparison requires isomer-specific quantification rather than a combined clomiphene measurement. The reasoning about lipophilic compounds and fat-containing meals altering absorption is general pharmacology, not an enclomiphene finding, and it should be read that way.

Other Compounds: What Has and Has Not Been Studied Together

The combination question most often raised concerns antiestrogens alongside aromatase inhibitors, since both classes influence estrogen signalling from different directions. In the verified set, the study that examined both classes against the same endpoint reported on regulation of plasma gonadotropin II secretion by sex steroids, aromatase inhibitors, and antiestrogens in the protandrous black porgy (PMID 11399474). That study is a comparative endocrine model in a fish species. It is not a human co-administration trial, and the results of a teleost gonadotropin model do not transfer directly to human endocrinology; researchers use such models to map mechanism, not to predict clinical combination outcomes.

The other compound-relevant observations in this set concern off-target pharmacology rather than combinations. The Ebola entry study reported that clomiphene and its isomers blocked viral particle entry and infection with similar potency (PMID 27490565), and researchers highlighted that the isomers behaved comparably despite their differing estrogen-receptor profiles — an observation consistent with an activity that does not depend on classical receptor binding. The endothelial cell work similarly reported channel-level activity for clomiphene (PMID 11156570). Both findings mean that discussions of "what enclomiphene might interact with" cannot be limited to estrogen-receptor ligands alone, at least at the concentrations used in those laboratory systems.

Evidence status at a glance

Enclomiphene Combinations and Adverse Events: What Studies Report

None of the verified studies reviewed here was designed as a safety study of enclomiphene combined with another substance, and none reported adverse events arising from such a combination. The human study in this set measured plasma concentrations of en- and zuclomiphene against ovulation induction in anovulatory women treated with clomiphene citrate (PMID 18353317) rather than tolerability of co-administered substances. The remaining three were laboratory or non-mammalian models — cultured endothelial cells (PMID 11156570), a viral entry assay (PMID 27490565) and a fish endocrine model (PMID 11399474) — in which human adverse-event reporting is not applicable. Any claim that a particular combination is tolerated, or that it is problematic, is not supported by the studies summarised on this page in either direction.

How to Read Interaction Claims in This Area

Several recurring patterns are worth recognising when evaluating statements about enclomiphene combinations:

1. Isomer substitution. Much of the pharmacology is published on clomiphene citrate, a mixture of enclomiphene and zuclomiphene. The Ebola entry study specifically compared the isomers and reported similar potency for that endpoint (PMID 27490565), but similarity on one endpoint does not imply similarity on all endpoints, which is precisely why the isomers were measured separately in the human plasma study (PMID 18353317).
2. Model species. Gonadotropin findings in the black porgy (PMID 11399474) describe a teleost reproductive system with its own sex-change biology; researchers treat such data as mechanistic, not translational.
3. In vitro concentration context. Cell-culture effects such as anion-channel inhibition (PMID 11156570) occur at concentrations set by the experiment, which may or may not correspond to concentrations reached in a living organism.
4. Absence framed as permission. The most common error is treating "no interaction study found" as "no interaction." The correct reading is that the question remains open.

Summary of the Evidence Position

Across the studies summarised here, researchers reported isomer-specific plasma measurement alongside an ovulation endpoint in treated women (PMID 18353317), comparable antiviral entry-blocking potency between clomiphene isomers in vitro (PMID 27490565), inhibition of volume-regulated anion channels by clomiphene in cultured endothelial cells (PMID 11156570), and modulation of plasma gonadotropin II secretion by sex steroids, aromatase inhibitors and antiestrogens in a fish model (PMID 11399474). None of these studies examined alcohol, caffeine or dietary state as a variable. Readers evaluating interaction claims are therefore looking at a field where mechanistic reasoning substantially outruns tested evidence, and where the honest description of most combination questions is that they have not been studied.

References

• Evaluation of the relationship between plasma concentrations of en- and zuclomiphene and induction of ovulation in anovulatory women being treated with clomiphene citrate (Fertility and Sterility, 2009)
• Clomiphene and Its Isomers Block Ebola Virus Particle Entry and Infection with Similar Potency: Potential Therapeutic Implications (Viruses, 2016)
• Inhibition of volume-regulated anion channels in cultured endothelial cells by the anti-oestrogens clomiphene and nafoxidine (British Journal of Pharmacology, 2001)
• Regulation of plasma gonadotropin II secretion by sex steroids, aromatase inhibitors, and antiestrogens in the protandrous black porgy, Acanthopagrus schlegeli Bleeker (Comparative Biochemistry and Physiology Part B, 2001)